Topiroxostat
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Trade names | Topiloric, Uriadec |
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 577778-58-6 |
| PubChem (CID) | 5288320 |
| ChemSpider | 4450517 |
| Chemical and physical data | |
| Formula | C13H8N6 |
| Molar mass | 248.24 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]
References[edit]
- ^ a b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan.
- ^ Hosoya, Tatsuo; Ohno, Iwao; Nomura, Shinsuke; Hisatome, Ichiro; Uchida, Shunya; Fujimori, Shin; Yamamoto, Tetsuya; Hara, Shigeko (2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. doi:10.1007/s10157-014-0935-8.
 |
This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
